About Nuage Therapeutics
Nuage Therapeutics is a company based in Barcelona (Spain) founded in 2021 by Judit Anido Folgueira, Mateusz Biesaga, Denes Hnisz, and Xavier Salvatella. Nuage Therapeutics has raised $13.1 million across 1 funding round from investors including Sofinnova Partners and Asabys Partners. Nuage Therapeutics offers products and services including Disordered Protein Therapies. Nuage Therapeutics operates in a competitive market with competitors including Radionetics, Hinova Pharmaceuticals, Convergent Therapeutics, Nymox Pharmaceutical and Glycomantra, among others.
- Headquarter Barcelona, Spain
- Founders Judit Anido Folgueira, Mateusz Biesaga, Denes Hnisz, Xavier Salvatella
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$13.1 M (USD)
in 1 rounds
-
Latest Funding Round
$13.1 M (USD), Seed
Jun 21, 2023
-
Investors
Sofinnova Partners
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nuage Therapeutics
Nuage Therapeutics offers a comprehensive portfolio of products and services, including Disordered Protein Therapies.
Innovative treatments targeting disordered proteins for cancer and diseases
Funding Insights of Nuage Therapeutics
Nuage Therapeutics has successfully raised a total of $13.1M through 1 strategic funding round. The most recent funding activity was a Seed round of $13.1 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nuage Therapeutics
Nuage Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Sofinnova Partners and Asabys Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Nuage Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nuage Therapeutics
Investment portfolio details for Nuage Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nuage Therapeutics
Detailed financials for Nuage Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nuage Therapeutics Comparisons
Peer comparison for Nuage Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nuage Therapeutics
Nuage Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Radionetics, Hinova Pharmaceuticals, Convergent Therapeutics, Nymox Pharmaceutical and Glycomantra, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Develops small molecule based drug for multiple disease treatment
|
|
| Locked | Locked | Locked |
Cancer therapeutics are developed using dual-targeted radionuclide therapy.
|
|
| Locked | Locked | Locked |
Provides research and development of novel drugs and diagnostic products for the aging population
|
|
| Locked | Locked | Locked |
Translational glycobiology research on galectin-3 inhibitors is conducted.
|
Detailed competitors of Nuage Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nuage Therapeutics
Complete news archive for Nuage Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuage Therapeutics
Nuage Therapeutics was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Nuage Therapeutics is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Judit Anido Folgueira is the current CEO of Nuage Therapeutics. They have also founded this company.
Nuage Therapeutics is a funded company, having raised a total of $13.1M across 1 funding round to date.
Nuage Therapeutics was founded in 2021 in Barcelona, Spain, within the biotechnology sector. Drug screening assays are developed to address intrinsically disordered proteins involved in biomolecular condensation. Treatments for castration-resistant prostate cancer are targeted through these efforts. Operations focus on innovative drug discovery methods, with a team of co-founders leading research and development activities in Europe.
Nuage Therapeutics's top competitors include Radionetics, Convergent Therapeutics and Emtora Biosciences.
Nuage Therapeutics offers Disordered Protein Therapies.
Nuage Therapeutics has 2 investors. Key investors include Sofinnova Partners, and Asabys Partners.